title: Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.
abstract: The Fas gene plays a key role in regulation of apoptotic cell death, and corruption of this signaling pathway has been shown to participate in immune escape and tumorgenesis. Single-nucleotide polymorphism in the promoter of Fas gene at position -670 A/G may affect its expression and play an important role in the pathology of many kinds of cancer. The association between Fas -670 A/G polymorphism and cancer risk is still controversial and ambiguous. Therefore, we conducted a meta-analysis of the currently literature to clarify this relationship. We conducted a search in the PubMed, EMbase, CNKI, and WanFang databases, covering all papers published by May 5, 2014. Overall, 59 case-control studies with 17,035 cases and 23,155 controls were retrieved based on the search criteria for cancer susceptibility related to -670 A/G polymorphism in Fas gene. Odds ratios (OR) and 95% confidence intervals (CI) revealed association strengths. Although no significant relationship was detected between Fas -670 A/G polymorphism and whole cancer risk, in the ethnicity subgroup, significant associations were found in three types of cancer: prostate cancer (OR = 1.06, 95% CI = 1.01-1.11 for A-allele vs. G-allele); hepatocellular carcinoma (OR = 0.89, 95% CI = 0.80-0.99 for AG vs. GG); esophageal cancer (OR = 0.95, 95% CI = 0.92-0.99 for AA + AG vs. GG). Moreover, lower cancer risk was found in smokers carried A-allele, when compared to smokers carried the GG genotype. The Fas -670 A/G polymorphism may be associated with esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility from our meta-analysis. Studies with larger samples and gene-environment interactions are warranted to understand the role of Fas -670 A/G polymorphism for cancer risk.
authors.affiliation: Department of Urology, The First Hospital of China Medical University, Shenyang, 110001, Peoples Republic of China.
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
authors.forename: Li
authors.initials: L
authors.lastname: Zuo
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.forename: Lei
authors.initials: L
authors.lastname: Yin
authors.forename: Kai
authors.initials: K
authors.lastname: Liang
authors.forename: Hongyuan
authors.initials: H
authors.lastname: Yu
authors.forename: Hui
authors.initials: H
authors.lastname: Ren
authors.forename: Wen
authors.initials: W
authors.lastname: Zhou
authors.forename: Hongwei
authors.initials: H
authors.lastname: Jing
authors.forename: Yang
authors.initials: Y
authors.lastname: Liu
authors.forename: Chuize
authors.initials: C
authors.lastname: Kong
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000235:genetics*; D016022:Case-Control Studies; D004938:Esophageal Neoplasms / Q000235:genetics*; D059647:Gene-Environment Interaction; D020022:Genetic Predisposition to Disease; D006801:Humans; D008113:Liver Neoplasms / Q000235:genetics*; D008297:Male; D011110:Polymorphism, Genetic / Q000235:genetics*; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics*; D019014:fas Receptor / Q000235:genetics*
chemical_list: C491901:FAS protein, human; D019014:fas Receptor
references.citation: Oncogene. 2001 Nov 1;20(50):7437-46
references.pmid: 11704875
references.citation: J Exp Med. 2005 Oct 3;202(7):967-74
references.pmid: 16186185
references.citation: Arch Biochem Biophys. 2011 Apr 15;508(2):185-91
references.pmid: 21036138
references.citation: Gynecol Oncol. 2013 Mar;128(3):584-9
references.pmid: 23234803
references.citation: Cancer Lett. 2006 Feb 20;233(1):21-7
references.pmid: 16473667
references.citation: J Natl Cancer Inst. 2004 Jul 7;96(13):1030-6
references.pmid: 15240787
references.citation: Zhonghua Zhong Liu Za Zhi. 2009 Jan;31(1):38-41
references.pmid: 19538867
references.citation: Eur J Gynaecol Oncol. 2009;30(2):142-4
references.pmid: 19480241
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:179-82
references.pmid: 16515587
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Cell Immunol. 1999 Feb 25;192(1):48-53
references.pmid: 10066346
references.citation: Leuk Lymphoma. 2012 Jul;53(7):1360-6
references.pmid: 22211869
references.citation: Cell. 1993 Dec 17;75(6):1169-78
references.pmid: 7505205
references.citation: Cancer J. 2007 Jul-Aug;13(4):233-7
references.pmid: 17762757
references.citation: Clin Chim Acta. 2010 Feb;411(3-4):179-83
references.pmid: 19895798
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Gynecol Oncol. 2005 Oct;99(1):113-8
references.pmid: 15996722
references.citation: J Endocrinol Invest. 2007 May;30(5):411-6
references.pmid: 17598974
references.citation: J Gastroenterol Hepatol. 2010 Mar;25(3):555-61
references.pmid: 20074157
references.citation: Cancer Detect Prev. 2007;31(3):225-32
references.pmid: 17561354
references.citation: Prostate Cancer Prostatic Dis. 2008;11(1):94-8
references.pmid: 17667965
references.citation: Rheumatology (Oxford). 1999 Sep;38(9):883-6
references.pmid: 10515651
references.citation: PLoS One. 2013 Aug 12;8(8):e71656
references.pmid: 23951214
references.citation: Science. 1995 Mar 10;267(5203):1449-56
references.pmid: 7533326
references.citation: Mol Immunol. 1997 Jun;34(8-9):577-82
references.pmid: 9393960
references.citation: Int J Mol Med. 2004 Sep;14(3):475-8
references.pmid: 15289903
references.citation: J Epidemiol. 2005 Nov;15(6):235-43
references.pmid: 16276033
references.citation: Lancet. 2014 Feb 8;383(9916):549-57
references.pmid: 24351322
references.citation: Prostate. 2011 Jul;71(10):1122-30
references.pmid: 21557277
references.citation: Intervirology. 2007;50(5):369-76
references.pmid: 17938571
references.citation: Stat Appl Genet Mol Biol. 2010;9:Article21
references.pmid: 20597847
references.citation: Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:282-90
references.pmid: 16343245
references.citation: Cell Death Differ. 2012 Jan;19(1):42-50
references.pmid: 21959933
references.citation: Clin Exp Obstet Gynecol. 2008;35(3):183-6
references.pmid: 18754288
references.citation: Carcinogenesis. 2007 May;28(5):1067-73
references.pmid: 17183065
references.citation: Gene. 2013 Jul 25;524(2):193-6
references.pmid: 23618817
references.citation: DNA Cell Biol. 2010 Oct;29(10):619-24
references.pmid: 20438363
references.citation: Eur J Clin Invest. 2001 Jun;31(6):550-3
references.pmid: 11422406
references.citation: J Dermatol Sci. 2010 Apr;58(1):78-80
references.pmid: 20219325
references.citation: Nat Rev Cancer. 2004 Nov;4(11):850-60
references.pmid: 15516958
references.citation: Genomics. 1992 Nov;14(3):821-2
references.pmid: 1385309
references.citation: Clin Cancer Res. 2008 May 15;14(10):3230-6
references.pmid: 18483392
references.citation: PLoS One. 2013;8(1):e53075
references.pmid: 23326385
references.citation: Cancer Res. 2003 Aug 1;63(15):4327-30
references.pmid: 12907599
references.citation: J Oral Pathol Med. 2010 Feb;39(2):155-61
references.pmid: 20359312
references.citation: JAMA. 2008 May 28;299(20):2423-36
references.pmid: 18505952
references.citation: Zhonghua Yu Fang Yi Xue Za Zhi. 2009 Jul;43(7):559-64
references.pmid: 19954064
references.citation: Mol Carcinog. 2010 Sep;49(9):810-7
references.pmid: 20572163
references.citation: J Leukoc Biol. 2008 Jan;83(1):220-2
references.pmid: 17962369
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):809-10
references.pmid: 11440968
references.citation: Zhonghua Gan Zang Bing Za Zhi. 2009 Aug;17(8):630-1
references.pmid: 19719928
references.citation: BMC Med Genet. 2011 Aug 24;12:112
references.pmid: 21864388
references.citation: J Mol Med (Berl). 2000;78(6):312-25
references.pmid: 11001528
references.citation: Int J Cancer. 2003 Jan 10;103(2):221-5
references.pmid: 12455036
references.citation: J Pediatr Hematol Oncol. 2007 Dec;29(12):815-21
references.pmid: 18090928
references.citation: Nature. 2001 May 17;411(6835):342-8
references.pmid: 11357141
references.citation: J Hum Genet. 2006;51(11):927-933
references.pmid: 17006606
references.citation: Biochem Genet. 2009 Aug;47(7-8):559-68
references.pmid: 19565204
references.citation: Anticancer Res. 2008 Jan-Feb;28(1A):97-103
references.pmid: 18383830
references.citation: Pharmacogenet Genomics. 2006 Apr;16(4):245-51
references.pmid: 16538171
references.citation: Urol Oncol. 2012 Sep;30(5):555-61
references.pmid: 20822933
references.citation: Pharmacogenet Genomics. 2006 Apr;16(4):253-63
references.pmid: 16538172
references.citation: Clin Cancer Res. 2006 Sep 15;12(18):5596-602
references.pmid: 17000697
references.citation: DNA Cell Biol. 2010 Jul;29(7):349-56
references.pmid: 20380574
references.citation: Lung Cancer. 2003 Oct;42(1):1-8
references.pmid: 14512182
references.citation: Carcinogenesis. 2007 Dec;28(12):2548-51
references.pmid: 17962219
references.citation: Pathol Oncol Res. 2014 Apr;20(2):367-74
references.pmid: 24218069
references.citation: Cancer Genet Cytogenet. 2008 Jan 1;180(1):1-5
references.pmid: 18068525
references.citation: Lung Cancer. 2006 Dec;54(3):303-8
references.pmid: 17014925